Durvalumab Injection

DRUG4 trials

Conditions

Advanced Biliary Tract CancerCancerHepatocellular CarcinomaLiver CarcinomaLiver Transplant; ComplicationsNSCLCNSCLC, Stage IIINon Small Cell Lung Cancer

Phase 1

BC3402 in Combination With Durvalumab in Patients With Advanced Hepatocellular Carcinoma

Not yet recruitingNCT06111326

Biocity Biopharmaceutics Co., Ltd.Hepatocellular Carcinoma

Start: 2023-10-31End: 2026-05-31Target: 83Updated: 2023-11-01

Phase 2

Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study

Active, not recruitingNCT04392505

Oslo University HospitalCancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Stage III +2

Start: 2020-05-11End: 2033-05-01Target: 100Updated: 2024-02-29

Phase 3

A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)

RecruitingNCT07229625

Suzhou Suncadia Biopharmaceuticals Co., Ltd.Advanced Biliary Tract Cancer

Start: 2026-01-21End: 2029-12-01Target: 604Updated: 2026-01-28

Unknown Phase

Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma ( Dulect2020-1 )

NCT04443322

RenJi HospitalLiver Carcinoma, Liver Transplant; Complications

Start: 2020-09-19End: 2025-12-31Target: 20Updated: 2020-09-22

Acta Oncologica2026-03-19

Blood-based tumor mutational burden as a biomarker in unresectable non-small cell lung cancer treated with chemoradiotherapy and durvalumab.

2025-10-22

ctDNA-based MRD detection in unresectable NSCLC undergoing curatively intended chemoradiotherapy and durvalumab.

Journal of Clinical Oncology2025-05-282 citations

Factors associated with failure to start consolidation durvalumab after definitive chemoradiation for locally advanced NSCLC

Frontiers in Oncology2023-07-053 citations

Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma (Dulect2020-1)

The Journal of Immunology2021-05-011 citations